NanoMedical Systems, Inc.

NanoMedical Systems develops novel drug-delivery devices based on its proprietary nStrada™ nanofluidics platform for sustained release of chronic therapies. These devices can be loaded with a variety of drugs including small molecules, peptides, and proteins for subcutaneous implantation. The nStrada™ devices rely on diffusion (passive or controlled) to achieve steady-state drug concentrations within a few days and then maintain constant release for the duration of the implant. This performance represents a significant improvement over polymer-based implants and depots which suffer from an initial burst release and multiple weeks to achieve steady-state concentrations.

NanoMedical Systems, Inc. headquartered in United States, North America, operates in the Biotechnology, Medical, Therapeutics, Nanotechnology sector. The company focuses on Biotechnology and has secured $653.3M in funding across 64 round(s). With a team of 11-50 employees, NanoMedical Systems, Inc. is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - NanoMedical Systems, Inc., raised $2.3M. Discover more about their projects, partnerships, and impact on our platform.